Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2023 · 10-Q
Revenue$310.17K$310.17K— vs Q3 2022 Net Income-$154.69K-$154.69KN/M vs Q3 2022 EPS Diluted-$0.02-$0.02N/M vs Q3 2022 Operating Income-$173,082N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-55.8%
Net margin-49.9%
ended May 31, 2023 · filed Jul 14, 2023 · 44 d after period end